<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194216</url>
  </required_header>
  <id_info>
    <org_study_id>53854</org_study_id>
    <nct_id>NCT04194216</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Rhinoplasty</brief_title>
  <official_title>Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy of a single intra-operative (intravenous) dose of
      &quot;cephalexin&quot; (first generation cephalosporin) or &quot;clindamycin&quot; (lincosamides), alone versus
      both intra-operative (intravenous) dose of &quot;cephalexin&quot; (first generation cephalosporin) or
      &quot;clindamycin&quot; (lincosamides) and postoperative oral dose of &quot;cephalexin&quot; or &quot;clindamycin&quot; use
      in nasal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 2 treatment arms:

      Treatment arm A: Intra-operative single intravenous(iv) dose of &quot;cephalexin&quot; 2 g or
      &quot;clindamycin&quot; 900 mg.

      Treatment arm B: Intra-operative single intravenous(iv) dose of &quot;cephalexin&quot; 2 g or
      &quot;clindamycin&quot; 900 mg and postoperative oral dose of &quot;cephalexin&quot; 250mg every 4 hours or
      &quot;clindamycin&quot; 150mg every 6 hours, for a duration of three days.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">April 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Applicable Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Infection Rate</measure>
    <time_frame>Seven days</time_frame>
    <description>Postoperatively, infection rates between treatment arms will be compared</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">864</enrollment>
  <condition>Nasal Obstruction</condition>
  <condition>Nasal Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-operative single intravenous(iv) dose of &quot;cephalexin&quot; 2 g or &quot;clindamycin&quot; 900 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-operative single intravenous(iv) dose of &quot;cephalexin&quot; 2 g or &quot;clindamycin&quot; 900 mg and postoperative oral dose of &quot;cephalexin&quot; 250mg every 4 hours or &quot;clindamycin&quot; 150mg every 6 hours, for a duration of three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-operative single intravenous(iv) dose of &quot;cephalexin&quot; 2 g or &quot;clindamycin&quot; 900 mg.</intervention_name>
    <description>Treatment Arm A</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <other_name>kelfex (cephalexin)</other_name>
    <other_name>cleocin (clindamycin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-operative single dose (iv) of &quot;cephalexin&quot; 2 g or &quot;clindamycin&quot; 900 mg and postoperative oral dose of &quot;cephalexin&quot; 250mg (every 4 hours) or &quot;clindamycin&quot; 150mg(every 6 hours) for 3 days</intervention_name>
    <description>Treatment Arm B</description>
    <arm_group_label>Treatment arm B</arm_group_label>
    <other_name>kelfex (cephalexin)</other_name>
    <other_name>cleocin (clindamycin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients (aged 18years and older)

        Exclusion Criteria:

          -  Prior rhinoplasty

          -  Any exogenous (non-nasal) grafts/implants

          -  Immune deficiency (DM, meds, other)

          -  History of radiotherapy to nose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam P Most, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Facial Plastic and Reconstructive Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facial Plastic and Reconstructive Surgery Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nuyen B, Kandathil CK, Laimi K, Rudy SF, Most SP, Saltychev M. Evaluation of Antibiotic Prophylaxis in Rhinoplasty: A Systematic Review and Meta-analysis. JAMA Facial Plast Surg. 2019 Jan 1;21(1):12-17. doi: 10.1001/jamafacial.2018.1187.</citation>
    <PMID>30489601</PMID>
  </reference>
  <reference>
    <citation>Ishii LE, Tollefson TT, Basura GJ, Rosenfeld RM, Abramson PJ, Chaiet SR, Davis KS, Doghramji K, Farrior EH, Finestone SA, Ishman SL, Murphy RX Jr, Park JG, Setzen M, Strike DJ, Walsh SA, Warner JP, Nnacheta LC. Clinical Practice Guideline: Improving Nasal Form and Function after Rhinoplasty Executive Summary. Otolaryngol Head Neck Surg. 2017 Feb;156(2):205-219. doi: 10.1177/0194599816683156.</citation>
    <PMID>28145848</PMID>
  </reference>
  <reference>
    <citation>Olds C, Spataro E, Li K, Kandathil C, Most SP. Postoperative Antibiotic Use Among Patients Undergoing Functional Facial Plastic and Reconstructive Surgery. JAMA Facial Plast Surg. 2019 Dec 1;21(6):491-497. doi: 10.1001/jamafacial.2019.1027.</citation>
    <PMID>31647506</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sam P. Most</investigator_full_name>
    <investigator_title>Professor and Chief, Division of Facial Plastic and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <keyword>Rhinoplasty</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

